SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

COGT

Cogent Biosciences, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed11d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The key catalyst is the November 30 PDUFA date for bezuclastinib in GIST; approval would trigger a commercial launch and potential revenue inflection. Monitor the ASH 2026 presentations (Dec 12-15) for SUMMIT trial data on symptom burden and the avapritinib-to-bezuclastinib switch sub-study.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$31.65
T+0 close · Nov 5, 2026 · via day close
Latest settled
−9.75%
T+5 · $28.56 · next T+20 in 20d
Vs SPY
−12.34%
α at T+5
Latest observation
−12.34%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $31.65entry
  2. T+1 · 8d ago +5.99%α +3.62% · $33.54
  3. T+5 · 4d ago −9.75%α −12.34% · $28.56
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cogent Biosciences reported Q3 2026 net loss of $111.4M, wider than the $80.9M loss in Q3 2025, driven by increased R&D and G&A spending ahead of the anticipated bezuclastinib launch. The company maintains a strong cash position of $791.1M, sufficient into late 2028, and is approaching three PDUFA dates starting November 30, 2026 for GIST.

Key Financial Metrics

Revenue
$0.00
est $0.00

Key Facts

  • Net loss of $111.4M in Q3 2026 vs $80.9M in Q3 2025
  • Cash, cash equivalents and marketable securities of $791.1M as of September 30, 2026
  • PDUFA target action date for bezuclastinib in GIST is November 30, 2026
  • PDUFA target action date for bezuclastinib in NonAdvSM is December 30, 2026
  • PDUFA target action date for bezuclastinib in AdvSM is June 29, 2027
  • R&D expenses were $75.1M in Q3 2026 vs $69.0M in Q3 2025
  • G&A expenses were $42.1M in Q3 2026 vs $14.4M in Q3 2025
  • IND applications for CGT1815 (pan-KRAS inhibitor) and CGT1145 (JAK2 V617F inhibitor) expected in Q4 2026

Financial Impact

Net loss of $111.4M in Q3 2026, cash burn of ~$1.2M from prior quarter; cash runway into late 2028

net losscash positionR&D expensesG&A expenses

Risk Factors

  • FDA non-approval or delayed action on any of the three bezuclastinib NDAs
  • Higher-than-expected cash burn from commercial readiness spending
  • Clinical trial execution risk for the PEAK extension cohort and pipeline IND filings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396995

Track record

13 reports on COGT

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 5/10 Viewing Entry $31.65 Now $27.44 −13.29% settles Feb 4
  4. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  5. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  6. Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  7. Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  8. Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  9. May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
  10. May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026